Literature DB >> 8605673

Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis.

J Guéchot1, A Laudat, A Loria, L Serfaty, R Poupon, J Giboudeau.   

Abstract

Diagnostic accuracy of two serum markers of liver fibrosis, hyaluronan (HA) and amino-terminal peptide of type III procollagen (P-III-P), was studied in a cohort of 326 untreated patients with chronic viral hepatitis C. Both P-III-P (RIA-gnost P-III-P, Behring Diagnostic) and HA (HA-test, Pharmacia) serum concentrations correlated with the histological grades of liver fibrosis (P < 0.001). Receiver-operating characteristic (ROC) curves showed that serum HA had greater diagnostic performance than P-III-P, both for discriminating patients with extensive liver fibrosis from those with no or mild fibrosis (area under the ROC curves: 0.864 vs 0.691, P <0.001) or for discriminating patients with cirrhosis from those without cirrhosis (area under the ROC curves: 0.924 vs 0.734, P <0.001). At cutoff values of 0.8 kU/L for serum P-III-P and 85 micrograms/L for serum HA, sensitivities were 70.0% and 64.5%, and specificities were 63.4% and 91.2%, respectively, for discriminating patients with extensive liver fibrosis from those with no or mild fibrosis. At the cutoff values of 1.0 kU/L for serum P-III-P and 110 micrograms/L for serum HA, sensitivities were 60.0% and 79.2%, and specificities were 74.0% and 89.4%, respectively, for discriminating patients with liver cirrhosis from those without cirrhosis. We conclude that, because the diagnostic accuracy of serum HA is greater than that of serum P-III-P as a marker of liver fibrosis, serum HA should be preferred when monitoring liver fibrosis in patients with chronic viral hepatitis C.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8605673

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  52 in total

1.  Fatty liver disease in children: eat now pay later.

Authors:  Ruth M L De Bruyne; Emer Fitzpatrick; Anil Dhawan
Journal:  Hepatol Int       Date:  2010-01-29       Impact factor: 6.047

Review 2.  Non-invasive diagnosis of liver fibrosis and cirrhosis.

Authors:  Yoav Lurie; Muriel Webb; Ruth Cytter-Kuint; Shimon Shteingart; Gerardo Z Lederkremer
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

Review 3.  Noninvasive diagnosis of liver fibrosis in patients with chronic hepatitis C.

Authors:  Laurent Castera; Jean-Michel Pawlotsky
Journal:  MedGenMed       Date:  2005-11-09

Review 4.  Non-invasive evaluation of hepatic fibrosis: don't count your chickens before they're hatched.

Authors:  M Pinzani
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

5.  Clinical Utility of Biomarkers of Liver Fibrosis.

Authors:  Keyur Patel; Don C Rockey
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-01

Review 6.  Recent advances in the pathogenesis and diagnosis of liver fibrosis.

Authors:  Natalie J Török
Journal:  J Gastroenterol       Date:  2008-07-01       Impact factor: 7.527

7.  Transient elastography for measurement of liver stiffness measurement can detect early significant hepatic fibrosis in Japanese patients with viral and nonviral liver diseases.

Authors:  Noriyuki Obara; Yoshiyuki Ueno; Koji Fukushima; Yu Nakagome; Eiji Kakazu; Osamu Kimura; Yuta Wakui; Osamu Kido; Masashi Ninomiya; Takayuki Kogure; Jun Inoue; Yasuteru Kondo; Masaaki Shiina; Takao Iwasaki; Takeshi Yamamoto; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2008-09-20       Impact factor: 7.527

8.  GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequencer-based serum protein glycomics.

Authors:  Dieter Vanderschaeghe; Wouter Laroy; Erwin Sablon; Philippe Halfon; Annelies Van Hecke; Joris Delanghe; Nico Callewaert
Journal:  Mol Cell Proteomics       Date:  2009-01-29       Impact factor: 5.911

9.  Relationship between clinical and pathologic findings in patients with chronic liver diseases.

Authors:  Lun-Gen Lu; Min-De Zeng; Yi-Min Mao; Ji-Qiang Li; De-Kai Qiu; Jing-Yuan Fang; Ai-Ping Cao; Mo-Bin Wan; Cheng-Zhong Li; Jun Ye; Xiong Cai; Cheng-Wei Chen; Ji-Yao Wang; Shan-Ming Wu; Jin-Shui Zhu; Xia-Qiu Zhou
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

10.  Usefulness of non-invasive markers for predicting significant fibrosis in patients with chronic liver disease.

Authors:  Han Hyo Lee; Yeon Seok Seo; Soon Ho Um; Nam Hee Won; Hanna Yoo; Eun Suk Jung; Yong Dae Kwon; Sanghoon Park; Bora Keum; Yong Sik Kim; Hyung Joon Yim; Yoon Tae Jeen; Hoon Jai Chun; Chang Duck Kim; Ho Sang Ryu
Journal:  J Korean Med Sci       Date:  2009-12-26       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.